Bayer Aktiengesellschaft

Bayeraktiengesellschaft

Klaus-Helmut Mohrs

Siegfried Raddatz

Michael Matzke

Romanis Fruchtmann

Reiner Muller-Peddinghaus

Armin Hatzelmann

Christian Kohlsdorfer

Pia Theisen-Popp

Joachim Mittendorf

Frank Mauler

J&ouml;rg Keldenich

Verena V&ouml;hringer

Arno Friedl

Reinhard Jork

Peter Spreyer

J&uuml;rgen Franz

J&uuml;rgen Dressel

Michael-Harold Rock

Hilmar Bischoff

Siegfried Goldmann

Stefan Wohlfeil

Ulrich E Muller

Martin Beuck

Dirk Denzer

Richard D Connell

Rudi Grutzmann

Joachim Schuhmacher

Ervin Horv&aacute;th

Matthias Decker

Jean Marie Viktor De Vry

Joachim Schumacher

Ervin Horv&agrave;th

Jean-Marie-Victor De Vry

Peter Fey

Rolf Angerbauer

Mazen Es-Sayed

Rudolf H Hanko

Matthias Muller-Gliemann

Hans-Christian Militzer

Ulrich Niewohner

Trevor S Abram

Graham Sturton

Hermann Arold

Rudiger Fischer

Gabriele Braunlich

Dieter Hoppe

Wendy J McDonald-Gibson

Axel Carstens

Steve Tudhope

John-Edward Butler-Ransohoff

Reiner M uller-Peddinghaus

The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Arylsulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

Aryl sulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

High enantio-selective process for producing pure enantiomeric

4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives are prepared by reacting quinoline-methoxy-phenyl-acetic acids with the corresponding glycinol derivatives, if appropriate with activation of the carboxylic acid function. The new compounds are suitable as active compounds in medicaments, in particular in antiatherosclerotic medicaments.

4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives

Oxy-phenyl-(phenyl)glycinolamides with heterocyclic substituents are prepared by reaction of the corresponding oxyphenylcarboxylic acids with heterocyclic substituents with phenylglycinol. The new substances are suitable as active compounds in medicaments, in particular in agents having an antiatherosclerotic action.

Oxy-phenyl-(phenyl)glycinolamides with heterocyclic substituents

Oxy-phenyl-(phenyl)gycinolamides with heterocyclic substituents are prepared by reaction of the corresponding oxyphenylcarboxylic acids with heterocyclic substituents with phenylglycinol. The new substances are suitable as active compounds in medicaments, in particular in agents having an antiatherosclerotic action.

Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives are prepared by reacting correspondingly substituted phenols with quinolylmethyl halides or by reacting unsubstituted phenols with quinolylmethyl halides and subsequent alkylation. The substituted quinol-2-yl-methoxy-phenylacetic acid derivatives may be employed as active substances in medicaments.

Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives

The Benzofuranyl- and -thiophenyl-alkane-carboxylic acid derivatives are prepared Tby cyclisation of hydroxy acetophenones and related compounds or by Wittig-reaction of benzofuranyl aldehydes. The compounds can be used to prepared medicaments.

Benzofuranyl-and-thiophenyl-alkanecarboxyclic acid derivatives

(Quinolin-2-yl-methoxy)phenylacetic acids are known as inhibitors of enzymatic reactions in the context of arachidonic acid metabolism. Enantiomerically pure (quinolin-2-yl-methoxy)phenylacetic acids can be prepared in a simple manner and in high purity and yield by diastereoselective alkylation of corresponding (quinolin-2-yl-methoxy)phenylacetic acid menthyl esters and subsequent specific removal of the ester radical with acids.

Enantiomerically pure intermediates for (quinolin-2-yl-methoxy)

The novel quinolin-2-yl-methoxybenzylhydroxyureas can be prepared by reaction of appropriate ketones with hydroxylamine and reduction of the ketoximes and subsequent reaction with isocyanates. The new substances can be employed as active substances in medicaments.

Quinolin-2-yl-methoxybenzylhydroxyureas

A (quinolin-2-yl-methoxy) phenylacyl-sulphonamide or -cyanamide of the formula ##STR1## and physiologically acceptable salts thereof. The (quinolin-2-yl-methoxy)phenylacylsulphonamide or -cyanamide is useful as an active compound in medicaments, particularly as a lipoxygenase inhibitor.

Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and

Quinolylmethoxyphenyl-acetamides of the formula: ##STR1## in which A, B, D, E, G, L and M are hydrogen, hydroxyl, halogen, cyano, carboxyl, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy or optionally substituted aryl;

Quinolylmethoxyphenyl-acetamides

Process for the preparation of enantiomerically pure substituted

Growing community of inventors

Wuppertal, Germany

Klaus-Helmut Mohrs